# National Research Corporation (NRC) Stock Analysis: Evaluating the 3.23% Dividend Yield Amidst Revenue Challenges

- Link: https://www.directorstalkinterviews.com/national-research-corporation-nrc-stock-analysis-evaluating-the-3-23-dividend-yield-amidst-revenue-challenges/4121247700
- Published: 2026-04-02T10:09:08+01:00
- Author: Madison Wilson

National Research Corporation (NASDAQ: NRC), a key player in the health information
services industry, offers a unique proposition for investors with its blend of robust
dividend yield and innovative solutions aimed at enhancing patient and employee 
experiences within healthcare organizations. Based in Lincoln, Nebraska, NRC has
carved a niche by providing analytics and insights designed to measure and improve
healthcare experiences across the United States.

**Market Position and Valuation**

NRC operates within the healthcare sector, focusing on health information services—
a segment poised to benefit from the growing demand for data-driven decision-making
in healthcare. With a market capitalization of $394.42 million, NRC stands as a 
mid-cap entity, offering both growth potential and stability. However, its current
trading price of $17.34 sits closer to the lower end of its 52-week range of $10.13
to $22.48, suggesting room for potential price appreciation.

Despite its apparent strengths, NRC’s valuation metrics are notably absent, with
no available P/E ratio, PEG ratio, or other typical valuation measures. This lack
of traditional valuation data could pose a challenge for potential investors seeking
a benchmark for comparison against industry peers.

**Performance Insights**

NRC’s latest financial performance highlights a revenue contraction of 4.60%, which
warrants attention from investors. The decline in revenue could be reflective of
broader challenges within its operating environment or transitional phases in its
service offerings. Nevertheless, the company boasts a significant return on equity(
ROE) of 51.24%, indicating efficient use of shareholder capital and a potentially
strong competitive position within its niche market.

The company has generated a free cash flow of $16.65 million, providing a cushion
for sustaining operations and supporting its dividend distribution amidst revenue
pressures.

**Dividend Appeal**

One of NRC’s standout features is its attractive dividend yield of 3.23%, a potentially
compelling factor for income-focused investors. However, the payout ratio of 104%
raises some red flags, indicating that the company is currently paying out more 
in dividends than it earns. This unsustainable payout level could lead to future
dividend cuts unless earnings improve.

**Analyst Sentiment and Technical Indicators**

Interestingly, NRC currently has no analyst coverage, with zero buy, hold, or sell
ratings, leaving the stock’s future direction relatively open to interpretation 
based on market dynamics and company performance. This absence of consensus can 
offer an opportunity for discerning investors to conduct independent analysis and
capitalize on market inefficiencies.

From a technical perspective, NRC’s stock shows a 50-day moving average of $16.24
and a 200-day moving average of $15.74, with an RSI (Relative Strength Index) of
35.20. An RSI below 30 typically suggests that a stock is oversold, but NRC’s RSI
of 35.20 indicates it’s approaching this range, potentially signaling a buying opportunity
if the downward pressure eases.

**Strategic Outlook**

NRC’s innovative offerings, such as the AI engine “Huey” for healthcare experience
management, position the company favorably in a technology-driven healthcare landscape.
Its diverse solutions, ranging from patient engagement to governance support, underscore
its comprehensive approach to healthcare analytics.

Investors with an appetite for dividend income may find NRC’s 3.23% yield attractive,
but they should remain vigilant of the high payout ratio. The company’s ability 
to navigate revenue challenges and leverage its unique market position will be critical
in sustaining shareholder returns.

Overall, National Research Corporation presents a mixed bag of potential risks and
rewards, making it a stock to watch closely for those interested in the intersection
of healthcare and analytics.

Share on: